ReBioCycle proves a portfolio of bioplastic sorting and recycling technologies within 3 complementary waste-processor-centric HUB at DEMO scale and in the real operational environment the effective and efficient recycling of 3x types of bioplastics (PLA, PHA, Mater-Bi) to demonstrate higher impact of obtaining the same or superior grade recycled polymers and other higher value applications. - NL HUB chemical technology upscaling to TRL 6. Using TORWASH technology to recycle PLA & PHA polymers (500 kg each. KPI: at least 1 m3 solution of monomers from each of PLA/PHA free of solids. The NCTP Group waste sorting site of Heerenveen (Friesland, NL) and TEC, PBM, Corbion will be involved. - IT HUB chemical technology upscaling to TRL 7. NOVAMONT technology will be used to recycle 600 kg of mixed composites including Mater-Bi. Also PHA from the NL and ES Hub will be tested in the IT HUB to blend into further Mater-Bi bioplastic formulations. IREN Group waste sorting site of Borgaro Torinese (Piedmont, Italy) and NOVAMONT’s new dedicated bioplastics recycling section within its Terni (IT) plant will be involved. - ES HUB Enzymatic recycling technology brought to TRL 6 , producing 50 kg within reactors of 200 litre s (CSIC (supported by AIMPLAS pre-treatment). Microbial recycling technology (by the AD “short-circuited” technology of GPB and UCD via pure culture fermentation ) brought to TRL 7 resulting outcomes 100kg rPHA (PHBV & PHBHx) and 20 kg rPHBV. Mechanical Technology upscaling to TRL 7 with the KPI level to be achieved 250 kg bioplastic recycle (TCD, AIMPLAS involved). HUB activities in SAV waste sorting site of Manises (Valencia, Spain). ReBioCycle will verify the industrial grade specifications by biopolymer brand owners and via demonstration of real-world products: durable (ARAPAHA: PLA) and multi-use packaging (SULAPAC: PHA and Mater-Bi). The LCA analysis by ARCHA and tailored D&E plan by partners EUBP and MAGFI will facilitate KER uptake.

Global terrestrial plant biodiversity remains a largely untapped source of natural bioactive compounds. In fact, valid sources are even “hiding in plain sight”, yet not “within reach” due to lack of effective technical solutions to unlock their potential. In this context, the PROSPLIGN consortium has developed an innovative bioprospecting approach that uses cutting-edge and complementary chemical and enzymatic methods, supported by statistical analysis and coupled with high-throughput detection methods, to enable the discovery of bioactive molecules from lignin, one of the fractions of the most abundant biopolymer on Earth (lignocellulose). Lignin “chemical biodiversity” will enable PROSPLIGN to cover three target markets (pharmaceuticals, cosmetics and fragrances) with a combined market of >€1.4 trillion. The project will use lignin derived from 9 different species and investigate at least 3 different chemical approaches and 10 different enzymes to obtain up to 1000 mixtures of lignin-derived compounds, and then pass a progressively narrower “hit validation funnel” in industrially relevant environments, being screened via up to 17 different bioactivity assays. Sustainable production routes for at least 2 of the most promising compounds per sector, directly or following derivatisation, will be proposed. Compared to traditional approaches, PROSPLIGN's bioprospecting avoids animal cruelty, expensive exploration efforts (no novel animal/plants discovery), disruptive extractions (seeking “hidden gems” in an abundant but underexploited “biomass mine”), and directly targets the liberation of readily testable bio/chemical-functionality present in plant material, superior to other approaches relying on “manipulation-intensive” microbial strain culture or “extrapolation” from DNA/RNA). Ultimately, PROSPLIGN will contribute to a new generation of biobased bioactives, unlocking more value from existing sources whose immense potential has yet to be harnessed.

Micro-Algae offer a solution to many of the European bioeconomy needs. Nevertheless, significant challenges still exist to their acceptance on the market, including organoleptic and functionality challenges. CleanAlgae2Value seeks to unlock such potential via a cascading approach to white-microalgae-derived medium-price ingredients, including protein isolates, oils, natural pigments and starch. The project will build and operate a replicable “upgrading-module” to drastically enhance relevant biorefineries performance via a cost-competitive, sustainable, and scalable microalgae fractionation and valorisation process for producing food-grade, medium-value, carbon-negative ingredients that exceed market standards. More specifically, the project will prove the effectiveness and efficiency of a “Micro-Algae Biorefinery Upgrade Module” (MABUM), able to unlock productions of protein isolates, protein concentrates, starch-rich fraction and oils (respectively 2, 1.3, 3.98 and 1.8 tons) to be validated into 15 prototypes, 13 for food and 2 for bio-packaging markets. The project will do so while increasing operative margins, by decreasing “value-normalised” CAPEX and OPEX, also thanks to modelling optimisation, contributing to market penetration. Importantly, CleanAlgae2Value would also benefit from synergies with a recently granted EIC Accelerator project, which focuses on upstream algae production from CO2 via SOL two-step fermentation, using solely CO2 as carbon source. The project brings together 16 organizations from 9 European countries, collaborating with end-users to produce added value ingredients. Holistic evaluations, including both empirical (surveys, workshops) and horizontal considerations (LCA, TEA, SSbD), will allow for the assessment of market acceptance and environmental, economic and societal sustainability, as well as further support and boost the project DCE activities and pathways towards EFSA positive opinion for those ingredients that still require it.